BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007;102:1709-19. [PMID: 17509028 DOI: 10.1111/j.1572-0241.2007.01282.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. Gastroenterology 2022;163:137-51. [PMID: 35738725 DOI: 10.1053/j.gastro.2022.04.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Elwing JE, Atassi H, Rogers BD, Sayuk GS. Emerging therapies in the management of Irritable Bowel Syndrome (IBS). Expert Opin Emerg Drugs 2022. [PMID: 35266839 DOI: 10.1080/14728214.2022.2052043] [Reference Citation Analysis]
3 Nee J, Lembo A. Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M). Aliment Pharmacol Ther 2021;54 Suppl 1:S63-74. [PMID: 34927757 DOI: 10.1111/apt.16625] [Reference Citation Analysis]
4 Wechsler EV, Shah ED. Diarrhea-Predominant and Constipation-Predominant Irritable Bowel Syndrome: Current Prescription Drug Treatment Options. Drugs 2021;81:1953-68. [PMID: 34727333 DOI: 10.1007/s40265-021-01634-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Barberio B, Savarino EV, Black CJ, Ford AC. Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis. Neurogastroenterol Motil 2021;:e14279. [PMID: 34672052 DOI: 10.1111/nmo.14279] [Reference Citation Analysis]
6 Sayuk GS. Medical Therapies for Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterol Clin North Am 2021;50:611-37. [PMID: 34304791 DOI: 10.1016/j.gtc.2021.04.003] [Reference Citation Analysis]
7 Barberio B, Savarino EV, Black CJ, Ford AC. Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00905-8. [PMID: 34425274 DOI: 10.1016/j.cgh.2021.08.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
8 Nickerson AJ, Rottgen TS, Rajendran VM. Activation of KCNQ (KV7) K+ channels in enteric neurons inhibits epithelial Cl- secretion in mouse distal colon. Am J Physiol Cell Physiol 2021;320:C1074-87. [PMID: 33852365 DOI: 10.1152/ajpcell.00536.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Rokkas T, Ekmektzoglou K, Niv Y. Comparative effectiveness of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a network meta-analysis of randomized controlled studies. Ann Gastroenterol 2021;34:535-46. [PMID: 34276193 DOI: 10.20524/aog.2021.0619] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
10 Bosman M, Elsenbruch S, Corsetti M, Tack J, Simrén M, Winkens B, Boumans T, Masclee A, Keszthelyi D. The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:459-73. [PMID: 33765447 DOI: 10.1016/S2468-1253(21)00023-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
11 Colomier E, Algera J, Melchior C. Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea. Front Pharmacol 2020;11:629026. [PMID: 33679391 DOI: 10.3389/fphar.2020.629026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Fukudo S, Okumura T, Inamori M, Okuyama Y, Kanazawa M, Kamiya T, Sato K, Shiotani A, Naito Y, Fujikawa Y, Hokari R, Masaoka T, Fujimoto K, Kaneko H, Torii A, Matsueda K, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol 2021;56:193-217. [PMID: 33538894 DOI: 10.1007/s00535-020-01746-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
13 Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol 2021;116:17-44. [DOI: 10.14309/ajg.0000000000001036] [Cited by in Crossref: 47] [Cited by in F6Publishing: 103] [Article Influence: 23.5] [Reference Citation Analysis]
14 Liu R, Staller K. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives. Drug Des Devel Ther 2020;14:1391-400. [PMID: 32308371 DOI: 10.2147/DDDT.S216056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Black CJ, Burr NE, Camilleri M, Earnest DL, Quigley EM, Moayyedi P, Houghton LA, Ford AC. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut 2020;69:74-82. [PMID: 30996042 DOI: 10.1136/gutjnl-2018-318160] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 35.5] [Reference Citation Analysis]
16 Brenner DM, Sayuk GS. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea. Adv Ther 2020;37:83-96. [PMID: 31707713 DOI: 10.1007/s12325-019-01116-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
17 Cangemi DJ, Lacy BE. Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions. Therap Adv Gastroenterol 2019;12:1756284819878950. [PMID: 31632456 DOI: 10.1177/1756284819878950] [Cited by in Crossref: 17] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
18 Ford AC, Moayyedi P, Chey WD, Harris LA, Lacy BE, Saito YA, Quigley EMM; ACG Task Force on Management of Irritable Bowel Syndrome. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2018;113:1-18. [PMID: 29950604 DOI: 10.1038/s41395-018-0084-x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 151] [Article Influence: 46.7] [Reference Citation Analysis]
19 Olden KW, Chey WD, Shringarpure R, Paul Nicandro J, Chuang E, Earnest DL. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. Current Medical Research and Opinion 2019;35:461-72. [DOI: 10.1080/03007995.2018.1533456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
20 Chang C. Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin. Clin Exp Gastroenterol 2018;11:335-45. [PMID: 30288076 DOI: 10.2147/CEG.S167031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
21 Lacy BE. Review article: An analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48:817-830. [PMID: 30194692 DOI: 10.1111/apt.14948] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
22 Zhu L, Ma Y, Ye S, Shu Z. Acupuncture for Diarrhoea-Predominant Irritable Bowel Syndrome: A Network Meta-Analysis. Evid Based Complement Alternat Med. 2018;2018:2890465. [PMID: 29977312 DOI: 10.1155/2018/2890465] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
23 Lacy BE, Nicandro JP, Chuang E, Earnest DL. Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint. Therap Adv Gastroenterol. 2018;11:1756284818771674. [PMID: 29774051 DOI: 10.1177/1756284818771674] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
24 Lee YY, Annamalai C, Rao SSC. Post-Infectious Irritable Bowel Syndrome. Curr Gastroenterol Rep 2017;19. [DOI: 10.1007/s11894-017-0595-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
25 Levio S, Cash BD. The place of eluxadoline in the management of irritable bowel syndrome with diarrhea. Therap Adv Gastroenterol 2017;10:715-25. [PMID: 28932272 DOI: 10.1177/1756283X17721152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Zheng Y, Yu T, Tang Y, Xiong W, Shen X, Jiang L, Lin L. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0172846. [PMID: 28291778 DOI: 10.1371/journal.pone.0172846] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 6.6] [Reference Citation Analysis]
27 Simrén M, Törnblom H, Palsson OS, Whitehead WE. Management of the multiple symptoms of irritable bowel syndrome. Lancet Gastroenterol Hepatol 2017;2:112-22. [PMID: 28403981 DOI: 10.1016/S2468-1253(16)30116-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 8.4] [Reference Citation Analysis]
28 Whitehead WE, Duffy K, Sharpe J, Nabata T, Bruce M. Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2017;45:14-26. [PMID: 27910150 DOI: 10.1111/apt.13839] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
29 Lucak S, Chang L, Halpert A, Harris LA. Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol 2017;10:253-75. [PMID: 28203283 DOI: 10.1177/1756283X16663396] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
30 Lacy BE. Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome. Int J Gen Med. 2016;9:7-17. [PMID: 26929659 DOI: 10.2147/ijgm.s93698] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
31 Lacy BE. Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome. Int J Gen Med. 2016;9:7-17. [PMID: 26929659 DOI: 10.2147/ijgm] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
32 Cash BD, Lacy BE, Rao T, Earnest DL. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? Expert Opin Pharmacother 2016;17:311-22. [PMID: 26559529 DOI: 10.1517/14656566.2016.1118052] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
33 Nee J, Zakari M, Lembo AJ. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome. Expert Opin Pharmacother 2015;16:2781-92. [PMID: 26558923 DOI: 10.1517/14656566.2015.1101449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
34 Nee J, Zakari M, Lembo AJ. Novel Therapies in IBS-D Treatment. Curr Treat Options Gastroenterol 2015;13:432-40. [PMID: 26432092 DOI: 10.1007/s11938-015-0068-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
35 Saps M, Biring HS, Pusatcioglu CK, Mintjens S, Rzeznikiewiz D. A Comprehensive Review of Randomized Placebo-Controlled Pharmacological Clinical Trials in Children With Functional Abdominal Pain Disorders. Journal of Pediatric Gastroenterology & Nutrition 2015;60:645-53. [DOI: 10.1097/mpg.0000000000000718] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
36 Choi CH, Kwon JG, Kim SK, Myung SJ, Park KS, Sohn CI, Rhee PL, Lee KJ, Lee OY, Jung HK, Jee SR, Jeen YT, Choi MG, Choi SC, Huh KC, Park H. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. Neurogastroenterol Motil. 2015;27:705-716. [PMID: 25809913 DOI: 10.1111/nmo.12544] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
37 Good L, Rosario R, Panas R. New therapeutic option for irritable bowel syndrome: Serum-derived bovine immunoglobulin. World J Gastroenterol 2015; 21(11): 3361-3366 [PMID: 25805945 DOI: 10.3748/wjg.v21.i11.3361] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
38 Fukudo S, Kaneko H, Akiho H, Inamori M, Endo Y, Okumura T, Kanazawa M, Kamiya T, Sato K, Chiba T, Furuta K, Yamato S, Arakawa T, Fujiyama Y, Azuma T, Fujimoto K, Mine T, Miura S, Kinoshita Y, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol. 2015;50:11-30. [PMID: 25500976 DOI: 10.1007/s00535-014-1017-0] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 10.6] [Reference Citation Analysis]
39 Garsed K, Chernova J, Hastings M, Lam C, Marciani L, Singh G, Henry A, Hall I, Whorwell P, Spiller R. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 2014;63:1617-25. [PMID: 24334242 DOI: 10.1136/gutjnl-2013-305989] [Cited by in Crossref: 138] [Cited by in F6Publishing: 127] [Article Influence: 17.3] [Reference Citation Analysis]
40 Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Quigley EM; Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109 Suppl 1:S2-26; quiz S27. [PMID: 25091148 DOI: 10.1038/ajg.2014.187] [Cited by in Crossref: 350] [Cited by in F6Publishing: 328] [Article Influence: 43.8] [Reference Citation Analysis]
41 Chang L, Lembo A, Sultan S. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014;147:1149-72.e2. [PMID: 25224525 DOI: 10.1053/j.gastro.2014.09.002] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 9.9] [Reference Citation Analysis]
42 Shah E, Pimentel M. Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome. Aliment Pharmacol Ther 2014;39:973-83. [DOI: 10.1111/apt.12692] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
43 Lewis JH. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. Expert Review of Gastroenterology & Hepatology 2014;4:13-29. [DOI: 10.1586/egh.09.72] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
44 Lacy BE, Oʼshana T. Clinical Pearls for Irritable Bowel Syndrome: Management of the Diarrhea-Predominant Subtype. Gastroenterology Nursing 2014;37:392-405. [DOI: 10.1097/sga.0000000000000056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Shah E, Triantafyllou K, Hana AA, Pimentel M. Adverse events appear to unblind clinical trials in irritable bowel syndrome. Neurogastroenterol Motil 2014;26:482-8. [PMID: 24350975 DOI: 10.1111/nmo.12289] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
46 Tong K, Nicandro JP, Shringarpure R, Chuang E, Chang L. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol 2013;6:344-57. [PMID: 24003335 DOI: 10.1177/1756283X13491798] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
47 Anastasi JK, Capili B, Chang M. Managing irritable bowel syndrome. Am J Nurs 2013;113:42-52; quiz 54, 53. [PMID: 23764698 DOI: 10.1097/01.NAJ.0000431911.65473.35] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
48 Boeckxstaens G, Corazziari ES, Mearin F, Tack J. IBS and the role of otilonium bromide. Int J Colorectal Dis. 2013;28:295-304. [PMID: 23178991 DOI: 10.1007/s00384-012-1598-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
49 Cremonini F, Nicandro JP, Atkinson V, Shringarpure R, Chuang E, Lembo A. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther. 2012;36:437-448. [PMID: 22779693 DOI: 10.1111/j.1365-2036.2012.05208.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
50 Olden KW. Targeted therapies for diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol. 2012;5:69-100. [PMID: 22754282 DOI: 10.2147/CEG.S290] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
51 Olden KW. Targeted therapies for diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol. 2012;5:69-100. [PMID: 22754282 DOI: 10.2147/CEG.S29023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
52 Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:991-1000. [PMID: 22613905 DOI: 10.1038/ajg.2012.131] [Cited by in Crossref: 204] [Cited by in F6Publishing: 217] [Article Influence: 20.4] [Reference Citation Analysis]
53 Cha BK, Choi CH, Chang SK. Efficacy of ramosetron in male patients with irritable bowel syndrome with diarrhea (neurogastroenterol motil 2011;23:1098-1104). J Neurogastroenterol Motil 2012;18:224-6. [PMID: 22523736 DOI: 10.5056/jnm.2012.18.2.224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
54 Shah E, Kim S, Chong K, Lembo A, Pimentel M. Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome. The American Journal of Medicine 2012;125:381-93. [DOI: 10.1016/j.amjmed.2011.08.026] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 5.0] [Reference Citation Analysis]
55 Harris LA, Heitkemper MM. Practical Considerations for Recognizing and Managing Severe Irritable Bowel Syndrome. Gastroenterology Nursing 2012;35:12-21. [DOI: 10.1097/sga.0b013e31823ff0e8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
56 Kwon JG, Park KS, Park JH, Park JM, Park CH, Lee KJ, Park HJ, Rhee JC; Korean Society of Neurogastroenterology and Motility. [Guidelines for the treatment of irritable bowel syndrome]. Korean J Gastroenterol 2011;57:82-99. [PMID: 21350320 DOI: 10.4166/kjg.2011.57.2.82] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
57 Lucak SL. Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. Therap Adv Gastroenterol 2010;3:165-72. [PMID: 21180598 DOI: 10.1177/1756283X10362277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
58 Saad RJ. Peripherally acting therapies for the treatment of irritable bowel syndrome. Gastroenterol Clin North Am. 2011;40:163-182. [PMID: 21333906 DOI: 10.1016/j.gtc.2010.12.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
59 Tsynman DN, Thor S, Kroser JA. Treatment of Irritable Bowel Syndrome in Women. Gastroenterology Clinics of North America 2011;40:265-90. [DOI: 10.1016/j.gtc.2011.03.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
60 Zakko S, Barton G, Weber E, Dunger-Baldauf C, Rühl A. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2011;33:1311-1321. [PMID: 21507028 DOI: 10.1111/j.1365-2036.2011.04656.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
61 Watier A, Rigaud J, Labat JJ. [Irritable bowel syndrome, levator ani syndrome, proctalgia fugax and chronic pelvic and perineal pain]. Prog Urol 2010;20:995-1002. [PMID: 21056377 DOI: 10.1016/j.purol.2010.08.060] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
62 Parikh N, Howden CW. The safety of drugs used in acid-related disorders and functional gastrointestinal disorders. Gastroenterol Clin North Am 2010;39:529-42. [PMID: 20951916 DOI: 10.1016/j.gtc.2010.08.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
63 Surawicz CM. Mechanisms of diarrhea. Curr Gastroenterol Rep. 2010;12:236-241. [PMID: 20532705 DOI: 10.1007/s11894-010-0113-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
64 Parikh N, Howden CW. The safety of drugs used in acid-related disorders and functional gastrointestinal disorders. Gastroenterol Clin North Am 2010;39:529-42. [PMID: 20951916 DOI: 10.1016/j.gtc.2010.08.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther. 2010;32:144-158. [PMID: 20412064 DOI: 10.1111/j.1365-2036.2010.04328.x] [Cited by in Crossref: 147] [Cited by in F6Publishing: 133] [Article Influence: 12.3] [Reference Citation Analysis]
66 Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol. 2010;105:866-875. [PMID: 20197759 DOI: 10.1038/ajg.2010.25] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
67 Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol 2009; 15(29): 3591-3596 [PMID: 19653335 DOI: 10.3748/wjg.15.3591] [Cited by in CrossRef: 96] [Cited by in F6Publishing: 89] [Article Influence: 7.4] [Reference Citation Analysis]
68 Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009;104:1831-43; quiz 1844. [PMID: 19471254 DOI: 10.1038/ajg.2009.223] [Cited by in Crossref: 193] [Cited by in F6Publishing: 165] [Article Influence: 14.8] [Reference Citation Analysis]
69 Adeyemo MA, Chang L. New treatments for irritable bowel syndrome in women. Womens Health (Lond) 2008;4:605-22; quiz 623. [PMID: 19072463 DOI: 10.2217/17455057.4.6.605] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
70 Stacher G. Cilansetron in the treatment of diarrhea-predominant irritable bowel syndrome? Expert Rev Gastroenterol Hepatol 2007;1:15-27. [PMID: 19072430 DOI: 10.1586/17474124.1.1.15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
71 Brandt LJ, Chey WD, Foxx-orenstein AE, Quigley EM, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Moayyedi P. An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome: . American Journal of Gastroenterology 2009;104:S8-S35. [DOI: 10.14309/00000434-200901001-00002] [Cited by in Crossref: 54] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
72 Heitkemper MM, Jarrett ME. Update on irritable bowel syndrome and gender differences. Nutr Clin Pract. 2008;23:275-283. [PMID: 18595860 DOI: 10.1177/0884533608318672] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
73 Camilleri M, Chang L. Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology 2008;135:1877-91. [PMID: 18848833 DOI: 10.1053/j.gastro.2008.09.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
74 Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther. 2008;30:884-901. [PMID: 18555935 DOI: 10.1016/j.clinthera.2008.05.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
75 Chang L. The trials and tribulations of drug development for functional gastrointestinal disorders. Neurogastroenterol Motil 2008;20 Suppl 1:130-8. [PMID: 18402650 DOI: 10.1111/j.1365-2982.2008.01093.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
76 Hammerle CW, Surawicz CM. Updates on treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14(17): 2639-2649 [PMID: 18461649 DOI: 10.3748/wjg.14.2639] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
77 Saad RJ, Chey WD. Recent developments in the therapy of irritable bowel syndrome. Expert Opinion on Investigational Drugs 2008;17:117-30. [DOI: 10.1517/13543784.17.2.117] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]